638
Participants
Start Date
May 5, 2016
Primary Completion Date
June 19, 2017
Study Completion Date
June 19, 2017
HOE901-U300 (Insulin Glargine 300 U/ml)
Self-administered by subcutaneous (SC) injection in the morning (between waking up and breakfast) using a pre-filled pen.
Lantus (Insulin Glargine 100 U/ml)
Self-administered by subcutaneous (SC) injection in the morning (between waking up and breakfast using a pre-filled pen.
Mandated back ground therapy
Rapid insulin analogs: e.g., insulin glulisine, insulin lispro or insulin aspart, used by participant at least 30 days before screening. Mealtime insulin was to be continued during the study and titrated towards protocol specified postprandial glucose targets (130-180 mg/dL).
Investigational Site Number 840-102, New York
Investigational Site Number 840-108, New York
Investigational Site Number 840-054, Hyattsville
Investigational Site Number 840-006, Rockville
Investigational Site Number 840-139, Bridgeport
Investigational Site Number 840-045, Greenville
Investigational Site Number 840-010, Morehead City
Investigational Site Number 840-080, Morehead City
Investigational Site Number 840-012, Lawrenceville
Investigational Site Number 840-008, Roswell
Investigational Site Number 840-014, Stockbridge
Investigational Site Number 840-001, Atlanta
Investigational Site Number 840-064, Columbus
Investigational Site Number 840-112, Ormond Beach
Investigational Site Number 840-137, Maitland
Investigational Site Number 840-133, Hialeah
Investigational Site Number 840-072, Coral Gables
Investigational Site Number 840-049, Miami
Investigational Site Number 840-076, Miami
Investigational Site Number 840-036, West Palm Beach
Investigational Site Number 840-114, Tampa
Investigational Site Number 840-047, Port Charlotte
Investigational Site Number 840-023, New Port Richey
Investigational Site Number 840-018, Palm Harbor
Investigational Site Number 840-053, Ocoee
Investigational Site Number 840-058, Chattanooga
Investigational Site Number 840-042, Lexington
Investigational Site Number 840-062, Covington
Investigational Site Number 840-123, Columbus
Investigational Site Number 840-104, Mentor
Investigational Site Number 840-037, Flint
Investigational Site Number 840-002, West Des Moines
Investigational Site Number 840-051, Fargo
Investigational Site Number 840-067, Billings
Investigational Site Number 840-125, Arlington Heights
Investigational Site Number 840-134, Crystal Lake
Investigational Site Number 840-011, Chicago
Investigational Site Number 840-073, Wichita
Investigational Site Number 840-033, Omaha
Investigational Site Number 840-142, Omaha
Investigational Site Number 840-094, Lincoln
Investigational Site Number 840-009, Metairie
Investigational Site Number 840-032, New Orleans
Investigational Site Number 840-151, Little Rock
Investigational Site Number 840-079, Norman
Investigational Site Number 840-029, Mesquite
Investigational Site Number 840-003, Dallas
Investigational Site Number 840-019, Dallas
Investigational Site Number 840-075, Dallas
Investigational Site Number 840-005, Dallas
Investigational Site Number 840-013, Dallas
Investigational Site Number 840-140, Lufkin
Investigational Site Number 840-026, Fort Worth
Investigational Site Number 840-048, North Richland Hills
Investigational Site Number 840-081, Houston
Investigational Site Number 840-160, Houston
Investigational Site Number 840-156, Houston
Investigational Site Number 840-152, Houston
Investigational Site Number 840-031, Houston
Investigational Site Number 840-150, Pearland
Investigational Site Number 840-153, El Paso
Investigational Site Number 840-046, Englewood
Investigational Site Number 840-039, Denver
Investigational Site Number 840-021, Denver
Investigational Site Number 840-070, Denver
Investigational Site Number 840-060, Idaho Falls
Investigational Site Number 840-097, Salt Lake City
Investigational Site Number 840-083, Murray
Investigational Site Number 840-101, Ogden
Investigational Site Number 840-040, Henderson
Investigational Site Number 840-017, Las Vegas
Investigational Site Number 840-044, Los Angeles
Investigational Site Number 840-022, Los Angeles
Investigational Site Number 840-132, Rolling Hills Estates
Investigational Site Number 840-024, Northridge
Investigational Site Number 840-063, Tarzana
Investigational Site Number 840-069, Pomona
Investigational Site Number 840-090, Pomona
Investigational Site Number 840-030, La Mesa
Investigational Site Number 840-149, Escondido
Investigational Site Number 840-124, La Jolla
Investigational Site Number 840-016, Ventura
Investigational Site Number 840-004, Fresno
Investigational Site Number 840-055, San Ramon
Investigational Site Number 840-110, Greenbrae
Investigational Site Number 840-129, Los Gatos
Investigational Site Number 840-130, San Jose
Investigational Site Number 840-096, Portland
Investigational Site Number 840-162, Bend
Investigational Site Number 840-015, Renton
Investigational Site Number 840-074, Spokane
Investigational Site Number 840-071, Concord
Investigational Site Number 840-028, Santa Barbara
Investigational Site Number 840-138, Tustin
Investigational Site Number 840-157, Framingham
Investigational Site Number 840-122, Waltham
Investigational Site Number 840-109, Staten Island
Investigational Site Number 840-143, Bennington
Investigational Site Number 840-056, Burlington
Investigational Site Number 840-111, Manatí
Lead Sponsor
Sanofi
INDUSTRY